Medpace Holdings Inc (NASDAQ:MEDP) CEO August J. Troendle sold 21,916 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $127.21, for a total transaction of $2,787,934.36. Following the transaction, the chief executive officer now owns 616,643 shares of the company’s stock, valued at $78,443,156.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
MEDP traded down $1.32 during trading on Friday, reaching $126.95. 196,772 shares of the stock traded hands, compared to its average volume of 317,375. The company has a quick ratio of 0.94, a current ratio of 0.94 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $4.45 billion, a PE ratio of 45.18 and a beta of 1.32. The stock’s 50-day moving average is $107.21 and its 200 day moving average is $91.18. Medpace Holdings Inc has a 12 month low of $58.72 and a 12 month high of $144.49.
Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, July 27th. The company reported $0.68 EPS for the quarter, beating the Zacks’ consensus estimate of $0.40 by $0.28. The business had revenue of $205.00 million for the quarter, compared to analysts’ expectations of $181.17 million. Medpace had a net margin of 12.11% and a return on equity of 16.05%. The business’s quarterly revenue was down 4.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.81 earnings per share. As a group, equities research analysts anticipate that Medpace Holdings Inc will post 3.64 EPS for the current year.
MEDP has been the subject of several research analyst reports. BidaskClub upgraded shares of Medpace from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 30th. Credit Suisse Group increased their price objective on Medpace from $92.00 to $114.00 and gave the company an “outperform” rating in a report on Tuesday, July 28th. Zacks Investment Research upgraded Medpace from a “hold” rating to a “strong-buy” rating and set a $137.00 price objective for the company in a report on Saturday, August 1st. SunTrust Banks increased their price objective on Medpace from $95.00 to $124.00 and gave the company a “hold” rating in a report on Wednesday, July 29th. Finally, Robert W. Baird upgraded Medpace from an “underperform” rating to a “neutral” rating and set a $83.00 price objective for the company in a report on Monday, June 8th. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Medpace presently has an average rating of “Buy” and a consensus target price of $103.29.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Jennison Associates LLC boosted its position in Medpace by 1.0% during the second quarter. Jennison Associates LLC now owns 10,013 shares of the company’s stock valued at $931,000 after acquiring an additional 97 shares during the last quarter. Natixis Advisors L.P. boosted its position in Medpace by 0.7% during the second quarter. Natixis Advisors L.P. now owns 19,227 shares of the company’s stock valued at $1,788,000 after acquiring an additional 130 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in Medpace by 1.4% during the second quarter. Oregon Public Employees Retirement Fund now owns 11,032 shares of the company’s stock valued at $1,026,000 after acquiring an additional 150 shares during the last quarter. Sheets Smith Wealth Management boosted its position in shares of Medpace by 4.7% during the 1st quarter. Sheets Smith Wealth Management now owns 3,707 shares of the company’s stock worth $272,000 after purchasing an additional 167 shares in the last quarter. Finally, Optimum Investment Advisors boosted its position in shares of Medpace by 3.3% during the 1st quarter. Optimum Investment Advisors now owns 6,200 shares of the company’s stock worth $455,000 after purchasing an additional 200 shares in the last quarter. 79.83% of the stock is currently owned by institutional investors and hedge funds.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Further Reading: Why is the Consumer Price Index (CPI) important?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.